Uzbekistan Digital Health Platform - Integrations
0.1.0 - ci-build
Uzbekistan Digital Health Platform - Integrations
0.1.0 - ci-build
Uzbekistan Digital Health Platform - Integrations - Local Development build (v0.1.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
| Rasmiy URL: https://terminology.dhp.uz/fhir/integrations/ConceptMap/dhis-observation-component-to-loinc | Versiya: 0.1.0 | ||||
| Draft 2026-07-13 holatiga ko‘ra | Kompyuterda qayta ishlanadigan nom: ObservationComponentToLoinc | ||||
Maps the local DHIS drug-susceptibility-test component codes to their LOINC [Susceptibility] code. Where the relationship is equivalent (plain drug-name agents), use the LOINC code directly in resources (see the DHIS Observation Component Code ValueSet); concentration-bearing agents are narrower and keep their local code. Non-drug component codes (interpretations, grading, identification flags) have no LOINC equivalent and are not listed.
Language: uz
Mapping from (not specified) to All LOINC codes
Mapping from DHIS Observation Component Code CodeSystemversion: 0.1.0) to LOINC
| Source Code | Relationship | Target Code |
| tub004-0007 (Rifampitsin (1,0 mg/ml)) | is narrower than | 18974-6 (Rifampin [Susceptibility]) |
| tub004-0008 (Izoniazid (0,1 mg/ml)) | is narrower than | 18934-0 (Isoniazid [Susceptibility]) |
| tub004-0009 (Etambutol (5,0 mg/ml)) | is narrower than | 18921-7 (Ethambutol [Susceptibility]) |
| tub004-0010 (Pirazinamid (100 mg/ml)) | is narrower than | 18973-8 (Pyrazinamide [Susceptibility]) |
| tub004-0011 (Levofloksatsin (2,0 mg/ml)) | is narrower than | 20629-2 (Levofloxacin [Susceptibility]) |
| tub004-0012 (Moksifloksatsin (1,0 mg/ml)) | is narrower than | 31039-1 (Moxifloxacin [Susceptibility]) |
| tub004-0013 (Moksifloksatsin (0,25 mg/ml)) | is narrower than | 31039-1 (Moxifloxacin [Susceptibility]) |
| tub004-0014 (Gatifloksatsin (0,25 mg/ml)) | is narrower than | 31038-3 (Gatifloxacin [Susceptibility]) |
| tub004-0015 (Amikatsin (1,0 mg/ml)) | is narrower than | 18860-7 (Amikacin [Susceptibility]) |
| tub004-0016 (Protionamid (2,5 mg/ml)) | is narrower than | 100057-9 (Prothionamide [Susceptibility]) |
| tub004-0017 (Linezolid (1,0 mg/ml)) | is narrower than | 29258-1 (Linezolid [Susceptibility]) |
| tub004-0018 (Klofazimin (1,0 mg/ml)) | is narrower than | 23627-3 (Clofazimine [Susceptibility]) |
| tub004-0019 (Bedaquilin (1,0 mg/ml)) | is narrower than | 94274-8 (Bedaquiline [Susceptibility]) |
| tub004-0020 (Delamanid (0,06 mg/ml)) | is narrower than | 93851-4 (Delamanid [Susceptibility]) |
| tub004-0021 (Pretomanid (1,0 mg/ml)) | is narrower than | 93850-6 (Pretomanid [Susceptibility]) |
| tub004-0025 (Ethionamide-Prothionamide) | is related to | 18922-5 (Ethionamide [Susceptibility]) |
| tub004-0022 (Rifampcin) | is equivalent to | 18974-6 (Rifampin [Susceptibility]) |
| tub004-0028 (Levofloxacin) | is equivalent to | 20629-2 (Levofloxacin [Susceptibility]) |
| tub004-0029 (Amikacin) | is equivalent to | 18860-7 (Amikacin [Susceptibility]) |
| tub004-0030 (Kanamycin) | is equivalent to | 18935-7 (Kanamycin [Susceptibility]) |